Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macromolecular immunosuppressants.

Theo Dingermann1, Ilse Zündorf

  • 1Institut für Pharmazeutische Biologie - Biozentrum, Marie-Curie-Str. 9, D-60439 Frankfurt/Main, Germany. Dingermann@em.uni-frankfurt.de

Biotechnology Journal
|August 8, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations.

Multiple sclerosis (Houndmills, Basingstoke, England)·2022
Same author

Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.

Mycoses·2017
Same author

New Knowledge About Old Drugs: The Anti-Inflammatory Properties of Cardiac Glycosides.

Planta medica·2017
Same author

Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.

Mycoses·2016
Same author

Evidence-Based Phytotherapy in Europe: Where Do We Stand?

Planta medica·2015
Same author

Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress.

Mediators of inflammation·2014
Same journal

Molecular Mechanisms of Cellulase Biosynthesis in Trichoderma reesei: Regulatory Networks, Secretion Pathways, and Environmental Modulation.

Biotechnology journal·2026
Same journal

The Impact of Collection Protocol on the Yield and Purity of Mesenchymal Stem Cell-Derived Extracellular Vesicles Isolated From Serum-Free Media.

Biotechnology journal·2026
Same journal

Biochemical and Functional Characterization of a Novel GH46 Chitosanase for Efficient Chitooligosaccharide Synthesis.

Biotechnology journal·2026
Same journal

LaeA Orchestrates Iron-Heme Supply and P450 Catalytic Efficiency for Enhanced Echinocandin B Biosynthesis in Aspergillus nidulans.

Biotechnology journal·2026
Same journal

Emerging Bioengineering Technologies in Female Reproduction: Preclinical Advances, Translational Challenges, and Future Outlook.

Biotechnology journal·2026
Same journal

Multi-Enzyme Cascade Reaction of Crude Enzyme Strategy for the Economical and Efficient Bioconversion of Rebaudioside A to Rebaudioside M.

Biotechnology journal·2026
See all related articles

Recombinant immunosuppressants target extracellular molecules for diverse therapeutic applications. Identifying relevant targets remains key to developing effective drugs in this rapidly advancing field.

Area of Science:

  • Immunology
  • Pharmacology
  • Biotechnology

Background:

  • Recombinant immunosuppressants are a diverse and significant class of drugs.
  • These drugs target extracellular molecules, including soluble factors and membrane proteins.
  • Many recombinant immunosuppressants have been developed rapidly, leveraging natural biological processes.

Purpose of the Study:

  • To highlight the development and characteristics of recombinant immunosuppressants.
  • To discuss the challenges and future directions in the field.
  • To emphasize the importance of target identification in drug development.

Main Methods:

  • Targeting extracellular molecules (soluble factors or membrane proteins).
  • Utilizing naturally derived proteins (e.g., human proteins like Anakinra) or antibody derivatives.

Related Experiment Videos

  • Leveraging the immune system of model organisms (mice, rats) for antibody development.

    • Main Results:

    • Recombinant immunosuppressants target complex molecular networks involved in cellular communication.
    • The development process relies on identifying relevant biological targets.
    • Clinical use is ongoing to determine true target relevance and drug efficacy.

    Conclusions:

    • Recombinant immunosuppressants represent a mature and evolving class of therapeutics.
    • Target identification is the primary challenge in developing novel immunosuppressive agents.
    • Further clinical evaluation is necessary to establish the efficacy of these drugs and their targeted pathways.